Latest Press Releases
Kibow Pharmaceuticals Announces Completion of First Patient in Phase II, 6 Months RCT of US-APR2020 and Enrollment in Subsequent 6 Months Open-Label Trial, a Unique Design of a Best-in-Class Add-on Treatment for Chronic Kindy Disease Patients
Kibow Pharmaceuticals LLC is a phase 2/3 clinical-stage company focused on developing novel live biotherapeutic products (LBP) for chronic kidney disease (CKD) patients. Kibow’s first clinical product, US-APR2020, is in a phase 2b multi-site global clinical trial and has recruited about half of the targeted 630 CKD stage 4 subjects since October 2021 (details on NCT04913272).
APR 13, 2021, 09:16 ET
Kibow Biotech Announces FDA Approval of IND to Initiate Phase II Clinical Trial of US-APR2020 to Treat Chronic Kidney Disease Stage IV
ibow Biotech, Inc., a clinical-stage biotechnology company pioneering the discovery and development of probiotics and prebiotics (synbiotics) for the treatment of kidney diseases beyond gut health, today announced that the U.S.
JUL 24, 2019, 08:48 ET
Kibow® Biotech Inc Supports President Trump’s Executive Order to Advance American Kidney Health with Expanded Plans to Develop Live Bio Therapeutic Product (LBP) as Drugs to Slow Progression to Dialysis
Kibow® Biotech Inc Supports President Trump’s Executive Order to Advance American Kidney Health with Expanded Plans to Develop Live Bio Therapeutic Product (LBP) as Drugs to Slow Progression to Dialysis
“The Trump administration has announced an ambitious plan to change treatment for kidney disease in the United States. President Trump signed an executive order on July 10thdirecting the Department of Health and Human Services [HHS] to develop policies addressing three goals: reducing the number of patients developing kidney failure, reducing how many Americans get dialysis treatment at dialysis centers, and making more kidneys available for transplant.” https://www.nytimes.com/2019/07/10/health/trump-kidney-disease- transplant.html
MAY 06, 2019, 08:39 ET
Kibow Biotech will Discuss RENADYL™, the World’s First and Only Use of Probiotics to Support Kidney Health at the 2019 National Kidney Foundation Spring Clinical Meeting in Boston, MA USA, May 9-12, 2019
Kibow Biotech, Inc., will feature its product for Kidney Illness, RENADYL™, at the 2019 National Kidney Foundation (NKF) Spring Clinical Meeting in Boston, MA, USA, May 9-12, 2019.
Kibow Biotech is the pioneer in the study of the “Gut Microbiome,” and the use of beneficial bacteria (probiotics) for a variety of serious illnesses.
APR 12, 2019, 16:55 ET
Kibow Biotech will present RENADYL™ at the 2019 American Nephrology Nurses Association (ANNA) in Dallas, Texas, USA, April 14-16, 2019
Kibow Biotech, Inc., Pennsylvania, will feature its product for Kidney Illness, RENADYL™, at the 50th Anniversary Meeting of the American Nephrology Nurse Association (ANNA) in Dallas, Texas, USA. (www.annanurse.org)
RENADYL™, the worlds first and only use of probiotics for those with kidney health issues will be presented to the Nephrology Nurses (i.e., nurses who are kidney health specialists) from across the country, at Hilton Anatole, Dallas, TX 75207, USA, April 12-15, 2019.
APR 11, 2019, 08:43 ET
Kibow Biotech, Inc. Presents its Latest Findings Highlighting Removal of Large Concentrations of Urea Besides Several Other Uremic Toxins Using Renadyl™ in CKD Applications at the ISN/WCN Conference in Melbourne, Australia, April 12-15, 2019
Kibow Biotech, Inc. is proud to present its recent findings, “Removal of Urea by Specific Probiotic Strain (KB19) in Chronic Kidney Disease Patients” (https://isnwcn2019.org/), during the poster presentation session at The World Congress of Nephrology (WCN) in Australia, April 12-15, 2019
Mar 14, 2019, 08:40 ET
Kibow Biotech Recognizes World Kidney Day — 2019
Kibow Biotech is pleased to announce that it will mark World Kidney Day, March 14, 2019, with a significant social media campaign to increase awareness of the importance of maintaining good kidney health. (Reference: worldkidneyday.org)
Feb 22, 2019, 08:31 ET
Indian High Court in Chennai Delivers a Decisive Product Patent Victory to Kibow Biotech Inc Specializing in Kidney Health Supplement “Renadyl™” – the Flagship Product for its “Enteric Dialysis®” Platform Technology
Kibow Biotech Inc is pleased to announce that it has achieved a significant victory with its India patent in a lawsuit brought by La Renon an Ahmedabad based company. [Patent No. 351/MUMNP/2006, 224100 “Compositions for Augmenting Kidney Function” Patent No. 224100, – issued September 29, 2008]. La Renon had challenged the validity of Kibow’s patent before India’s specialized IP tribunal, the Intellectual Property Appellate Board (IPAB) in 2013. The IPAB dismissed the challenge and upheld Kibow’s patent. The Madras High Court has now validated the IPAB order and effectively upheld Kibow’s patent once again.
Jun 04, 2018, 08:47 ET
Kibow® Biotech to Present Its Breakthrough and Proven “Enteric Dialysis®” Technology at BIO 2018 International Convention, June 4-7 in Boston, MA, USA (www.BIO.org).
This annual convention is the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
May 04, 2018, 08:15 ET
Kibow® Biotech to Participate in The Pediatric Academic Societies (PAS) 2018 Meeting, May 5-8, 2018 in Toronto, Canada
Kibow Biotech is pleased to be exhibiting for the first time at The Pediatric Academic Societies (PAS) Meeting, May 5-8, 2018 in Toronto, Canada, (https://www.pas-meeting.org/ ) where it will introduce its plan to develop clinical studies for pediatric CKD patients using its innovative dietary supplement product, Renadyl™, the first and only kidney health supplement formulated and developed with pharmaceutical like validation, which utilizes revolutionary “Enteric Dialysis®” technology.
Mar 08, 2018, 12:53 ET
On World Kidney Day Centaur Pharmaceuticals & Kibow® Biotech, USA, Announce a Strategic Alliance to Market Renadyl in India for Chronic Kidney Illness
– Prevalence of Chronic Kidney Illness in India is 17.2% and rising[1].
– Dialysis is a painful and expensive process with scarcely available resources.
– This novel, US-patented, and clinically-tested product helps maintain healthy kidney functions.
Feb 28, 2018, 08:45 ET
Kibow Fortis® Recently Featured at the 2018 Integrative Healthcare Symposium in New York, NY.
Kibow® Biotech, the 20-year-old Research & Development Company and creator of the World’s first probiotic kidney health supplement Renadyl™, are announcing the availability of Kibow Fortis® a premium multi-fiber prebiotic supplement. Kibow Fortis, the world’s most comprehensive multi-fiber supplement is comprised of 6 prebiotic fibers. Other fiber supplements primarily use only psyllium husk and methylcellulose; these fibers alone can’t work as well as Kibow Fortis®. The product was recently featured at the 2018 Integrative Healthcare Symposium in New York, New York. Recently, healthcare practitioners have expressed serious interest in the prebiotic multi-fiber formulation for its ability to promote the formation of high amounts of Short Chain Fatty Acids (SCFAs), specifically the formation of propionate and butyrate. SCFAs have been studied for their importance in regulating the immune system, strengthening the epithelial lining. Decades of research by Kibow®’s leading team of microbiome scientists have allowed Kibow® Biotech to formulate Kibow Fortis® with science in mind.
Nov 20, 2017, 07:15 ET
Global $10 Billion Probiotics Dietary Supplement Market 2017-2022 – Key Players are DowDuPont, Chr. Hansen Holding A/S, Royal DSM N.V., Cargill. Lifeway Foods, and Kibow Biotech
The “Probiotics Dietary Supplement Market – Forecasts from 2017 to 2022” report has been added to Research and Markets’ offering.
Probiotics dietary supplement market is projected to witness a CAGR of 8.09% during the forecast period to reach a total market size of US$10.225 billion by 2022, increasing from US$6.928 billion in 2017
Shifting people focus towards health and fitness is augmenting the need for nutritional diet while propelling demand for probiotics dietary supplements.
Oct 31, 2017, 08:35 ET
Kibow® Biotech’s “Enteric Dialysis®” Technology and Its Renadyl™ Product Formulation for Maintaining Healthy Kidney Function Is to Showcase Its Ultimate Validation at the Annual ASN 2017 – Kidney Week Conference.
Kibow® Biotech is proud to announce its twentieth year of operations as a leader in the kidney health supplement marketplace. For the past 13 years, Kibow® has been participating and exhibiting at the annual meeting of the American Society of Nephrology: Kidney Week event (https://www.asn-online.org/kidneyweek/) educating nephrology professionals on the crucial role of the gut-kidney connection, dysbiosis, and modulation of the Gut Microbiome with its innovative “Enteric Dialysis®” technology.
Oct 24, 2017, 08:40 ET
Revolutionary, Non-Invasive, Cost Effective Renal Technology Working 24/7 Shows It Helps Maintain Healthy Kidney Function
For 20 years, Kibow® Biotech has been refining a novel approach to maintaining healthy kidney function “Enteric Dialysis®”. Enteric Dialysis® utilizes probiotics (yes, probiotics) to metabolize the waste products (toxins) building up in the bloodstream due to reduced kidney function. Kibow® Biotech will be exhibiting for the 13th consecutive year at the annual American Society of Nephrology conference in New Orleans, Louisiana
Oct 11, 2017, 08:45 ET
Kibow® Biotech Celebrates 20 Years of Operations With Further Validation of Its “Enteric Dialysis®” Technology, and Renadyl™ Product Formulation for Maintaining Healthy Kidney Function
Kibow® Biotech is proud to announce its twentieth year of operations as a leader in the kidney health supplement marketplace. Nine out of 10 biotech companies fail within the first five years of business; Kibow® has managed to stay on the cutting edge of science with its product Renadyl™ based on “Enteric Dialysis®” technology. Renadyl™ is the first and only kidney health supplement formulated to maintain healthy kidney function.
Jun 20, 2017, 08:35 ET
Kibow® Biotech Inc. (Buzz of Bio Winner, 2014) Receives US Patent for Gout/Hyperuricemia Product Formulation Based on Modulation of the Gut Microbiome With Probiotics and Prebiotics
Kibow® Biotech Inc., a pioneer in developing “Enteric Dialysis®” technology, is pleased to announce the issuance of a new patent covering a unique method for preventing or treating gout or hyperuricemia by the U.S. Patent and Trademark Office on May 23rd 2017.
Mar 09, 2017, 08:35 ET
Kibow® Biotech Inc. to Support the World Kidney Day (March 9th) With an Independent Educational Webinar on “Obesity and Chronic Kidney Disease” and Modulating the “Gut Microbiome With Pro/Prebiotics” Based on Its Novel “Enteric Dialysis®” Technology Formulation
Nov 15, 2016, 08:40 ET
Kibow® Biotech Further Validates RENADYL™ Towards Failing Kidney Function and its Original Concept Kibow® Biotech Further Validates RENADYL™ Towards Failing Kidney Function and its Original Concept “Will the Bowel be the Kidney of Future?” With Greater Understanding and Recognition in the #1 Emerging Field of Microbiome
Nov 12, 2015, 08:45 ET
This year’s annual American society of Nephrology (ASN) 2015 Kidney Week conference was held at the San Diego Convention Center, Nov 3 – 8 https://www.asn-online.org/education/kidneyweek/archives/future.aspx. Kibow® Biotech, Inc. was pleased to mark its 10th year of continuous…
More news about: Kibow® Biotech, Inc. , American Society of Nephrology (ASN) 2015 Kidney Week
Jun 16, 2015, 08:45 ET
The most prestigious and highly acclaimed annual event of the BIO-2015 is being held in Philadelphia – June 15-18. This International Convention is hosted by the Biotechnology Industry Organization (http://convention.bio.org/about-bio-convention/ ). Kibow® Biotech, Inc. is…
More news about: Kibow® Biotech
Nov 11, 2014, 08:30 ET
Kibow® Biotech To Showcase Renadyl™ and Support ASN 2014 Theme For Kidney Health in Philadelphia
The American Society Of Nephrology (ASN) and more than 13,000 other kidney professionals from across the globe will be participating at Kidney Week 2014 in Philadelphia Convention Center, Pennsylvania. The world’s premier nephrology professional annual meeting, Kidney Week provides…
More news about: Kibow® Biotech Inc.
Sep 22, 2014, 08:30 ET
The Harvard Medical School – Division of Nutrition will be hosting its annual symposium on probiotics on Sept 22 and 23 in Boston, MA. This symposium is intended to provide an overview of the latest scientific evidence related to gut microbiota and probiotics and their importance across the…
More news about: Kibow® Biotech , Harvard Medical School , Renadyl
May 07, 2014, 08:30 ET
Pennsylvania Probiotic Dietary Supplement Company Wins Biotech Innovation Award
Kibow® Biotech is delighted to be announced a winner of this year’s BIO International Convention (June 23 – 26), Buzz of BIO Contest. The Pennsylvania based company is one of the four winners in this year’s contest recognizing the most innovative companies in the biotech sector. …
More news about: Kibow® Biotech
Apr 15, 2014, 08:30 ET
Kibow® Biotech is pleased to participate in the Buzz of BIO for the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 23-26, 2014 at the San Diego Convention Center in California. During the…
More news about: Kibow® Biotech
Mar 14, 2014, 08:45 ET
Kibow® Biotech is pleased to announce that March 13, on the occasion of World Kidney Day (worldkidneyday.org), it joined with Apollo Hospital Group (Chennai, India) to honor Dr. Eli A. Friedman, M.D., M.A.C.P., F.A.C.P., with a Lifetime Achievement Award, celebrating his excellence and…
More news about: Kibow® Biotech, Inc.
Mar 13, 2014, 08:35 ET
Kibow® Biotech Marks World Kidney Day with Introduction of Renadyl™ Product to India Market
Kibow® Biotech is pleased to announce that it will mark World Kidney Day (March 13, worldkidneyday.org) with the launch of Renadyl™, its patented, clinically validated probiotic dietary supplement for kidney health, in India. This milestone event will coincide with Kibow®’s participation…
More news about: Kibow® Biotech, Inc.
